Abstract-The natriuretic peptides are considered to be cardioprotective; however, their receptors have not been identified in human myocardium using radiolabeled analogs. Dendroaspis natriuretic peptide (DNP) has been recently identified as a new member of this peptide family and is thought to be less susceptible to enzymatic degradation. Therefore, we have developed the novel radiolabeled analog [ 125 I]-DNP and used this to localize high-affinity (K D ϭ0.2 nmol/L), saturable, specific binding sites in adult human heart (nϭ6) and coronary artery (nϭ8). In competition binding experiments, atrial natriuretic peptide and brain type natriuretic peptide had greater affinity for [
T he heart contributes to the regulation of cardiovascular homeostasis by synthesizing and secreting 2 natriuretic peptide hormones: atrial natriuretic peptide (ANP) 1 and brain type natriuretic peptide (BNP). 2 ANP and BNP protect the heart from volume overload by inducing potent natriuresis, diuresis, and vasodilatation. Other cardiac protective roles involve attenuation of cardiac hypertrophy, suppression of both the renin-angiotensin-aldosterone system and sympathetic nervous system activity, while enhancing vagal reflexes. 3 These effects result in decreased preload and after-load to the heart, which further prevents the development of pathologic cardiac hypertrophy and the progression to heart failure (HF).
In situations of cardiac stress, the heart responds by increasing the secretion of natriuretic peptides from the ventricles, resulting in significantly enhanced circulating levels of ANP 4 and BNP. 5 The plasma concentration of these peptides, in particular BNP, has been strongly associated with the degree of left ventricular dysfunction and is being used as a diagnostic and prognostic marker for HF. 6, 7 Despite the increase in circulating ANP and BNP, the natriuretic, diuretic, and vasodilatory efficacy of these peptides are dramatically reduced in HF. 8, 9 This may reflect increased metabolism or clearance of natriuretic peptides from circulation and/or downregulation of functional natriuretic peptide receptors (NPRs), although other mechanisms, such as desensitization of NPR-A, 10 may also be involved.
Three NPR have been identified to date, 2 of which, NPR-A and NPR-B (also known as GC-A and GC-B, respectively), 11 couple to particulate guanylyl cyclase (GC). ANP and BNP bind with high affinity to NPR-A, 12 whereas C-type natriuretic peptide (CNP) binds with high affinity to NPR-B. 12 The third NPR functions predominantly as a nonspecific natriuretic peptide clearance receptor (NPR-C) 13 but has also been shown to activate the pertussis toxin-sensitive protein G i . 14 Although NPR-C is nonselective for the endogenous natriuretic peptides, the ANP analog des-[Glu 18 Ser 19 Gly 20 Leu 21 Gly 22 ]-ANF-(4-23)-NH 2 (cANF) demonstrates higher selectivity for NPR-C over the other NPR. 12 In adult human heart, binding sites for [ 125 I]-ANP have been detected on the endocardial endothelial cells 15 but not to the myocardium. This is surprising because mRNA transcripts for all 3 NPRs have been identified in the myocardium, 16 consistent with in vitro studies 17, 18 that demonstrate that ANP potently attenuates hypertrophy of human cardiomyocytes. Therefore, despite considerable research into the cardiovascular physiology of natriuretic peptides, determination of NPR distribution, density, and identity at the protein level in adult human heart and also in the vasculature has been inconclusive. 15, 19, 20 Hence, there is little information regarding the characterization of NPR-A in adult human heart and whether progression to HF alters NPR-A density, which may contribute to the reduced efficacy of endogenous and exogenous natriuretic peptides in patients, where synthetic BNP (nesiritide) has been approved for the treatment of acute decompensated HF (http://www.fda.gov/cder/approval/ index.htm).
Recently, a novel natriuretic peptide was identified from the venom of the Green Mamba snake (Dendroaspis angusticeps) and consequently named Dendroaspis natriuretic peptide (DNP). 21 Although a DNP homolog has not yet been identified by bioinformatic analysis of the human genome, immunoreactivity (IR) to this peptide has been detected in human tissues, 22 whereas circulating levels have been demonstrated to correspond to the degree of HF. 23 The physiological function of DNP is similar to ANP, inducing natriuresis 24 and vasodilatation. 22 Interestingly, neutral endopeptidase 24.11(NEP) does not affect DNP-mediated effects in animals, 25 suggesting that DNP may have enhanced resistance to degradation. We hypothesized, therefore, that a radiolabeled analog of DNP could be used to localize the distribution of NPR-A and to determine whether receptor density is altered in HF.
Therefore, we synthesized a novel radioiodinated analog of DNP, [
125 I]-DNP (Figure 1 ), and our aims were to (1) determine whether [
125 I]-DNP can be used to visualize receptors in adult human heart tissue; (2) characterize receptors in adult human left ventricle and coronary artery based on pharmacological criteria of saturable, specific and highaffinity binding characteristics; (3) determine the identity of [
125 I]-DNP binding sites; (4) confirm the distribution of NPR-A in human heart and coronary artery using molecular biological and immunocytochemical techniques; and (5) monitor alterations of receptor density in left ventricle and coronary artery of patients with HF.
Materials and Methods
An expanded Materials and Methods section is in the online data supplement, available at http://circres.ahajournals.org
Tissue Samples
Human heart tissue and coronary artery were obtained from patients, with informed consent and local ethical approval, undergoing cardiac transplantation for either dilated cardiomyopathy (DCM) (nϭ12) or ischemic heart disease (IHD) (nϭ14) or were from donor heart (nϭ10), for which there were no suitable recipients. The coronary artery from DCM patients was considered to be histologically normal. 26 All tissues were sectioned at 30-m thickness. Patient details are summarized in Table 1 . washing, sections were measured for radioactivity using a gamma counter.
Cardiovascular Tissue Profiling by Receptor Autoradiography

Specificity of [ 125 I]-DNP Binding
Sections of left ventricle were preincubated with binding buffer and then incubated with 0.2 nmol/L [ 125 I]-DNP in the presence and absence of 1 mol/L of the structurally related peptides ANP, BNP, CNP, and DNP as well as structurally unrelated peptides angiotensin II (Ang II), apelin-13, bradykinin (BK), endothelin-1 (ET-1), ghrelin, guanylin, somatostatin-14 (SST-14), and vasoactive intestinal peptide (VIP), at 22°C, for 1 hour. After washing, sections were measured for radioactivity using a gamma counter. 
Competition Binding Studies
Fluorescence Dual Staining and Confocal Microscopy Image Analysis
Cryostat-cut sections of left ventricle and coronary artery were fixed in acetone, blocked with 5% goat serum, and incubated with rabbit anti-NPR-A serum at 1:300 dilution and either mouse anti-von Willebrand factor (vWF) monoclonal antibody at 1:50 dilution or mouse anti-smooth muscle ␣-actin (SM␣A) at 1:100 dilution, in PBS/T containing 1% goat serum, for 72 hours, at 4°C. After washing in PBS/T, sections were incubated with the secondary antibody solution containing both AlexaFluor 488 conjugated goat anti-rabbit serum (1:200 dilution) and AlexaFluor 568 conjugated goat anti-mouse serum (1:200 dilution), for 1 hour, at 22°C. Following a final wash, sections were mounted using Vectashield mounting medium and images analyzed.
RT-PCR Assays
Left ventricle, right atria, and coronary artery smooth muscle mRNA was extracted using Invitrogen Micro-FastTrack 2.0 Kit according to the protocol of the manufacturer. Synthesis of cDNA was performed using Invitrogen SuperScript III First-Strand Synthesis System. RT-PCR conditions and specific primers for human NPR-A were designed based on published data. 27 Control reactions were performed with primers for ␤-actin on cDNA. PCR products were separated by electrophoresis on a 1% agarose gel with ethidium bromide. RT-PCR primer-specific reaction product sizes were estimated by reference to a 100-bp DNA molecular weight standard.
Data and Statistical Analysis
The data from binding studies were analyzed using the iterative, nonlinear curve fitting programs in the KELL package (Biosoft, Cambridge, UK). Pooled K D, B max (normalized to fmol/mg protein), and Hill slope were expressed as meanϮSEM. Data were compared using Student's 2-tailed unpaired t test as appropriate. Multiple comparisons were evaluated by ANOVA. Statistical significance was taken as PϽ0.05. [
Results
Cardiovascular Tissue Profiling by Receptor Autoradiography
I]-DNP Competition Binding in Human Heart
To verify the identity of 
RT-PCR Assay
RT-PCR primer-specific reaction products of the expected size for NPR-A were detected in human left ventricle, right atria, and smooth muscle of coronary artery ( Figure 4C ).
Primer-specific reaction products for ␤-actin, used as a positive control, were detected in cDNA. Bands were not visible when primers for NPR-A and ␤-actin were omitted.
Immunocytochemistry
NPR-A IR was localized to cardiomyocytes and small intramyocardial vessels of left ventricle ( Figure 5A and 5B) received from donor hearts. No staining was detected in adjacent sections when the primary antibody was omitted ( Figure 5C ). 125 I]-DNP binding sites (A), whereas CNP (nϭ4) and cANF (nϭ4) compete with lower affinity (B). The derived rank order of affinity was DNPϾBNPϷANPϾ ϾcANFϾCNP. C, RT-PCR primer-specific reaction products (arrow, 491 bp) for human NPR-A detected from RNA extracted from coronary artery (CA) smooth muscle (nϭ3), left ventricle (LV) (nϭ3), and right atria (RA) (nϭ3). Primers for ␤-actin were used as positive control (ϩ) on cDNA. Bands were not visible when primers were omitted (-).
Fluorescence Dual Staining and Confocal Microscopy Image Analysis
The distribution of NPR-A was further determined using fluorescence dual-labeling techniques, revealing that IR to NPR-A colocalized with SM␣A IR in intramyocardial vessels ( Figure 5D through 5F ). However, NPR-A IR did not colocalize with vWF IR in the endothelium of these vessels ( Figure 5G through 5I) . In contrast, NPR-A IR did colocalize with vWF IR in the endocardial endothelial cells of the left ventricle ( Figure 5J through 5L) . Furthermore, the green fluorescence signal for NPR-A IR displayed striation-type patterns in the tissue surrounding intramyocardial vessels, which is typical of a cardiomyocyte distribution. In epicardial coronary artery, NPR-A IR did not colocalize with vWF IR in the endothelium ( Figure 6D through 6F) but did colocalize with SM␣A IR (Figure 6A through 6C) . 
Downregulation of [ 125 I]-DNP Binding Density in Heart Failure
We measured the density of NPR-A in the coronary artery and left ventricle of HF patients to determine whether alterations in NPR-A density may contribute to the significant attenuation of natriuretic peptide efficacy reported in this patient group. [
125 I]-DNP binding was saturable and bound with high affinity to left ventricle from DCM and IHD patients ( Table 2 ). The affinity of binding in both patient groups was comparable to that in donor left ventricle. However, the density of binding sites (B max ) was significantly (PϽ0.005) downregulated in left ventricle of patients with IHD.
Compared with histologically normal epicardial coronary artery, the density of binding sites was significantly (PϽ0.05) downregulated in coronary artery from patients with IHD, without significant alterations in the affinity of binding ( Table 2 ). Hill coefficients were close to unity in all saturation binding experiments, suggesting binding of [
125 I]-DNP was with a single affinity.
Discussion
We have reported for the first time the binding characteristics of the novel snake venom ligand [
125 I]-DNP in adult human left ventricle and coronary artery. The initial aim of our study was to ascertain whether [ 125 I]-DNP could be used to determine the distribution of NPR in adult human heart tissue. Profiling of cardiovascular tissue, using receptor autoradiography, demonstrated that [ 125 I]-DNP binding sites were present throughout the myocardium of human heart. Binding of [
125 I]-DNP to small intramyocardial vessels, to smooth muscle of large epicardial coronary arteries, and to endocardial endothelial cells was also detected. This latter observation was in agreement to a previous study using [
125 I]-ANP, where binding sites were only detected in adult human endocardial endothelial cells. 15 Therefore, our study overlaps with and greatly expands on the distribution of NPR in adult human heart tissue.
The density of NPR-A, measured by [ 125 I]-DNP in the left ventricle (Ϸ6 fmol/mg protein), was comparable to that of the Ang II receptors (Ϸ3 fmol/mg protein) 28 and also to receptors for the emerging cardiovascular peptides apelin (Ϸ8 fmol/mg protein) 29 and ghrelin (Ϸ6 fmol/mg protein). 30 In contrast, the density of NPR-A in both the left ventricle and coronary artery (Ϸ8 fmol/mg protein) was Ϸ10-fold lower than the density of ET-1 receptors in these tissues (Ϸ65 fmol/mg protein 31 and Ϸ71 fmol/mg protein 32 in human left ventricle and coronary artery, respectively).
In specificity experiments, only the 3 endogenous natriuretic peptides, ANP, BNP, and CNP, inhibited [
125 I]-DNP, whereas a range of structurally unrelated cardiovascular peptides did not compete. Interestingly, ANP and BNP inhibited binding of [
125 I]-DNP comparable to DNP, suggesting that NEP does not differentially influence the binding of these peptides to receptors on left ventricle. VIP, a ligand with high affinity for NPR-C, 14 was inactive, confirming that [
125 I]-DNP radioligand was not binding to NPR-C. Importantly, guanylin, which binds another member of the particulate GC-receptor family, GC-C, 33 did not compete. At the highest concentration tested (1 mol/L), all 3 natriuretic peptide competed for [ 125 I]-DNP binding, with CNP inhibiting binding to a lesser extent, consistent with rank orders of potency reported for these peptide at the NPR-A receptor. 34, 35 In left ventricle, ANP, BNP, and DNP competed monophasically with comparable affinity for [
125 I]-DNP binding sites. In contrast, CNP competed with Ϸ30-, 40-, and 70-fold lower affinity when compared with ANP, BNP, and DNP, respectively. Similarly, cANF competed with Ϸ14-, 17-, and 30-fold lower affinity in comparison with ANP, BNP, and DNP, respectively. The rank order of potency from our study was DNPϾBNPϷANPϾ ϾcANFϾCNP, which is consistent with the rank order of potency of agonists that would be expected for NPR-A. 12 Our data therefore provided strong evidence for the specific binding of [
125 I]-DNP to NPR-A in human heart. This is also in agreement with the reported action of DNP in inducing natriuresis 24 and vasodilatation, 22 both considered to be attributable to NPR-A activation.
The expression of NPR-A in adult human heart was confirmed using immunocytochemistry, which paralleled the distribution visualized by [
125 I]-DNP, with NPR-A IR present throughout the ventricular myocardium. The identity of cells expressing the receptor was determined and included the endocardial endothelial cells and smooth muscle cells of intramyocardial vessels, but not the endothelium, the latter in agreement with functional studies. 36 Comparable distribution of NPR-A IR was visualized in epicardial coronary artery, colocalizing with the smooth muscle but not to the endothelium of these vessels. To confirm that these tissues were capable of synthesizing the receptor, mRNA encoding NPR-A was detected in the smooth muscle of coronary artery, left ventricle, and right atrium, consistent with the literature. 16, 37 The presence of NPR-A receptors in myocytes as well as endocardial and smooth muscle cells suggests that the latter cell types may potentially also contribute to the significant downregulation in receptor number in the myocardium of patients with IHD.
The physiology of NPR-A agonists, such as ANP, in the vasculature is well established, inducing potent and efficacious endothelium independent vasodilatation, in both small resistance vessels 36 and large conduit arteries. 36, 38 Further-more, it has recently been reported that endogenous ANP modulates the smooth muscle tone of smaller veins and venules. 39 This suggests that NPR-A may be important in the regulation of vascular smooth muscle tone in a range of vessels. Interestingly, in patients with HF, the efficacy of both endogenous and exogenously infused natriuretic peptide induced vasodilatation is significantly reduced 9,40 when compared with healthy volunteers. In our study, we report that the density of NPR-A in coronary artery is significantly downregulated in IHD patients compared with histologically normal coronary artery. Therefore, this may result in loss of natriuretic peptide induced vasodilatation in coronary arteries supplying the heart.
In contrast to the vasculature, the role of natriuretic peptides on ventricular hemodynamics is less well understood. Although ANP is regarded as a negative inotrope, data supporting this is inconsistent and often contradictory. 41 However, in vitro studies 17, 18 have demonstrated natriuretic peptides to have potent antihypertrophic effects on cardiomyocytes. Mouse knockout models of the gene encoding NPR-A (Npr1) validate these in vitro studies, as Npr1 Ϫ/Ϫ mice develop hypertension, cardiac fibrosis, and exaggerated cardiac hypertrophy. 42, 43 To verify that hypertrophy is not the consequence of hypertension, a recent study developed a mouse model with selective disruption of Npr1 in cardiomyocytes. 44 These mice did not develop hypertension but exhibited significant cardiac hypertrophy. In agreement with these in vivo and in vitro studies, the size of cardiomyocytes was significantly reduced in mice with cardiomyocyte-specific overexpression of Npr1 when compared with wild-type mice. 45 Mechanisms other than reduction of NPR-A density may also contribute to the reduced efficacy of natriuretic peptides in HF patients. Both NPR-C density and mRNA have been reported to be significantly increased in platelets 46 and left ventricle, 47 respectively, of patients with HF. The latter study also monitored mRNA expression levels of NPR-A in left ventricles of nonfailing and IHD patients but found no significant differences. This suggests that the alterations in receptor density observed in the present study involve posttranslational mechanisms. Furthermore, NEP activity is also significantly increased during progression to HF. 48 Therefore, our observed downregulation in NPR-A density in patients with IHD, together with receptor desensitization 10 as well as increased metabolism and clearance of natriuretic peptides following release from the cardiomyocytes, may all contribute to the reported blunted natriuretic peptide response in patients with HF.
In conclusion, we have synthesized and characterized a novel radioligand, [
125 I]-DNP, and quantified, for the first time to our knowledge, NPR-A in adult human heart and cardiac vessels. Cells expressing NPR-A were identified by immunocytochemistry. Using this radioligand, we have discovered the density of NPR-A was significantly reduced in cardiac tissues from patients with IHD. [
125 I]-DNP will allow further quantification of changes in NPR-A to understand the role of these receptors in both human disease and in animal models following targeted disruption of the natriuretic system
